J&J challenges AstraZeneca in lung cancer with PhIII PFS winnews2023-09-28T15:09:46+00:00September 28th, 2023|Endpoints News|
Immunovant’s $450M; Oncopeptides reassesses Pepaxti strategy in Europe; Akebia resubmits kidney drugnews2023-09-28T15:01:03+00:00September 28th, 2023|Endpoints News|
BioNTech reiterates presence in Africa; WuXi eyes first Chinese vaccine plant; Chinese drugmaker blocks FDA checksnews2023-09-28T14:49:06+00:00September 28th, 2023|Endpoints News|
Biogen’s R&D pruning hits digital health as biotech scraps 23,000-person Apple studynews2023-09-28T14:42:43+00:00September 28th, 2023|Endpoints News|
Merck to participate in Medicare negotiations process ‘under protest,’ following at least three othersnews2023-09-28T14:06:03+00:00September 28th, 2023|Endpoints News|
GSK’s ViiV to lean on long-acting HIV portfolio ahead of dolutegravir patent expirationnews2023-09-28T13:20:03+00:00September 28th, 2023|Endpoints News|
Harbinger Health raises $140M Series B to launch liquid biopsy for early cancer detection by 2025news2023-09-28T12:00:58+00:00September 28th, 2023|Endpoints News|
Abcam founder urges investors to vote against Danaher’s $5.7B buyout, seeks to return as CEOnews2023-09-28T11:08:39+00:00September 28th, 2023|Endpoints News|
FDA panel recommends agency reject BrainStorm’s ALS drug after company filed over protestnews2023-09-27T22:00:23+00:00September 27th, 2023|Endpoints News|
Gritstone inks up to $433M contract with BARDA for 10,000-person Covid-19 vaccine trial news2023-09-27T20:01:40+00:00September 27th, 2023|Endpoints News|
